Investors that are looking for some new shares to buy may want to look at the ones listed below.
While these three ASX 200 shares are from different areas of the market, one thing they have in common is that they have been tipped to climb higher from here.
Here’s what you have to know about them:
Goodman Group (ASX: GMG)
The first ASX 200 share that could be in the buy zone is Goodman. It is a global integrated commercial and industrial property company with operations throughout Australia, New Zealand, Asia, Europe, the United Kingdom, North America and Brazil. Goodman has a world class portfolio of properties which have exposure to key growth markets such as ecommerce and logistics. Given the strong demand it is experiencing and its huge development pipeline, Citi believes it is well-placed for growth over the coming years.
Its analysts currently have a buy rating and $29.50 price target on its shares. This implies potential upside of almost 33% for investors.
ResMed Inc. (ASX: RMD)
Another ASX 200 share to look at is ResMed. It is a medical device company with a focus on the sleep treatment market. ResMed has been a very strong performer over the last decade and looks well-placed to continue this strong form over the next decade. This is thanks to its world class products, significant market opportunity, and the growing prevalence of sleep disorders. Its near term performance is also being boosted by a 5.2 million CPAP device recall from Philips.
Morgans is a fan of the company and has an add rating and $40.46 price target on ResMed’s shares. This suggests potential upside of 23% over the next 12 months.
Westpac Banking Corp (ASX: WBC)
A final ASX 200 share to look at is Westpac. This banking giant’s shares are down notably from their highs. This has been driven by concerns about its margins and cost cutting plans. However, the team at Morgans believe the challenges facing Westpac are not unsurmountable. As a result, it doesn’t believe its shares should be priced like a value trap and feels its recent update should alleviate concerns over its cost outlook.
The broker has an add rating and $29.50 price target on its shares. This implies potential upside of almost 30% for investors over the next 12 months.
The post Analysts name 3 ASX 200 shares with potential upside of 20%+ appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of January 12th 2022
More reading
- 2 blue chip ASX 200 shares analysts rate as buys
- Own Westpac (ASX:WBC) shares? Here’s the latest on the bank’s cost-cutting crusade
- Analysts name 2 ASX 200 blue chip shares to buy
- Should you be buying ASX 200 bank shares in February?
- The Westpac (ASX:WBC) share price has gained less than $4 in 10 years. Have the dividends been worth it?
Motley Fool contributor James Mickleboro owns Westpac Banking Corporation. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. and Westpac Banking Corporation. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/NYubGr0